Patents Examined by Lynn A. Bristol
  • Human monoclonal anti-PD-L1 antibodies and methods of use
    Patent number: 9828434
    Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: November 28, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Jianhua Sui
  • Anti-c-Met/anti-Ang2 bispecific antibody
    Patent number: 9808507
    Abstract: An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: November 7, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seungja Oh, Kyung Ah Kim, Bo Gyou Kim, Seung Hyun Lee, Ji Min Lee
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 9803029
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 31, 2017
    Assignee: AMPHIVENA THERAPEUTICS, INC.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Modified antibody
    Patent number: 9796787
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: October 24, 2017
    Assignee: Vaccibody A/S
    Inventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie
  • Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
    Patent number: 9789182
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: October 17, 2017
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, INNATE PHARMA
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre
  • Antibody constructs for CDH19 and CD3
    Patent number: 9765157
    Abstract: The present invention provides a bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds a human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct in the treatment of melanoma, and a kit comprising the antibody construct.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: September 19, 2017
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, Peter Kufer, Patrick Hoffmann, Tobias Raum, Ralf Lutterbüse, Elisabeth Nahrwold, Claudia Blumel
  • Antibodies with improved half-life in ferrets
    Patent number: 9738702
    Abstract: The antibodies, immunoglobulin constructs, or immunoglobulin fusion proteins whose in vivo half-life is increased in ferrets by a modified ferret IgG Fc region can be useful to test therapeutics in ferrets and ferret models.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: August 22, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Thomas Nesspor, Bernard Scallon
  • Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor
    Patent number: 9730926
    Abstract: Pharmaceutical composition including a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor and a method of preventing and/or treating cancer including co-administering a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor to a subject in need thereof.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: August 15, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Powei Lin, Kwang Ho Cheong, Young Jun Koh, Jae-woong Hwang, Seung Hyun Lee, Jung Wook Lee
  • Anti-Ly6E antibodies and immunoconjugates and methods of use
    Patent number: 9724427
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: August 8, 2017
    Assignee: Genentech, Inc.
    Inventors: Chie Sakanaka, Peter Chang
  • Bispecific antibody molecule
    Patent number: 9718893
    Abstract: The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: August 1, 2017
    Assignee: SYNIMMUNE GMBH
    Inventors: Gundram Jung, Michael Durben, Ludger Grosse-Hovest
  • Anti-NTB-A antibodies and related compositions and methods
    Patent number: 9708404
    Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 18, 2017
    Assignee: Seattle Genetics, Inc.
    Inventors: Timothy S Lewis, Che-Leung Law
  • Antibodies that bind to human programmed death ligand 1 (PD-L1)
    Patent number: 9709568
    Abstract: The present disclosure provides isolated antibodies that specifically bind to human PD-L1, as well as antigen binding fragments of such antibodies, and kits comprising the anti-PD-L1 antibodies or binding fragments and a set of reagents for detecting a complex of the antibody, or antigen binding fragment thereof, bound to human PD-L1. The antibodies and antigen binding fragments of this disclosure are useful for immunohistochemical detection of human PD-L1 expression in tissue samples. Nucleic acid molecules encoding the antibodies and antigen binding fragments of this disclosure, as well as expression vectors and host cells for expression thereof, are also provided.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 18, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert H. Pierce, Patricia Bourne, Linda Liang, Michael Bigler
  • Anti-NGF antibodies and methods using same
    Patent number: 9708398
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: July 18, 2017
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Jaume Pons, Arnon Rosenthal
  • Antibody light chains
    Patent number: 9708388
    Abstract: The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid and vectors.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: July 18, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventor: Roland Beckmann
  • Method for regulating cell proliferation
    Patent number: 9695235
    Abstract: The present invention provides a composition for regulating cell proliferation comprising a peptide having a partial amino acid sequence of BBF2H7 or an antibody capable of binding to the peptide. The problem has been solved by preparation of the peptide having a partial amino acid sequence of BBF2H7 which has a cell proliferation activity.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: July 4, 2017
    Assignee: Hiroshima University
    Inventors: Kazunori Imaizumi, Atsushi Saito
  • Hetero-dimeric immunoglobulins
    Patent number: 9683052
    Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: June 20, 2017
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Stanislas Blein, Darko Skegro, Paul Wassmann
  • Hetero-dimeric immunoglobulins
    Patent number: 9683053
    Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: June 20, 2017
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Stanislas Blein, Darko Skegro, Paul Wassmann
  • Anti SEZ6 antibodies and methods of use
    Patent number: 9676850
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: June 13, 2017
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Laura Saunders, Scott J. Dylla, Orit Foord, Robert A. Stull, Michael Torgov, Hui Shao, David Liu
  • Anti-C-Met/anti-Ang2 bispecific antibody
    Patent number: 9637541
    Abstract: An anti-c-Met/anti-Ang2 bispecific antibody, a composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method of preventing and/or treating a cancer in a subject including administering the anti-c-Met/anti-Ang2 bispecific antibody to the subject.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: May 2, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hyung-Chan Kim, Kyung Eun Kim, Yoon Sook Lee, Mi Young Cho
  • Antibody Fc mutants with ablated effector functions
    Patent number: 9637549
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region reduce binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: May 2, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: William Strohl, Omid Vafa